JEA BizDev Consulting, LLC®

Find your next opportunity.

HomeConnecting science. Creating value.PagesServicesExpertise across the BD value chainPagesAbout JohnExperience behind the partnershipsPagesOur approachFrom strategy to signed agreementPagesOpportunitiesExplore assets for partneringPagesTrack recordPartnerships and downloadable deal summariesPagesStart a conversationDiscuss an opportunity with JohnPagesMy cross-border dealsJEA reference library on Google DriveTransactionsCross-border deal libraryJEA reference library on Google DriveTransactionsDLL3 ADCOncology · IND Filing · DLL3AssetsHER2 Biparatopic ADCOncology · Phase 3 · HER2AssetsFRα Biparatopic ADCOncology · IND Filing · FRαAssetsCYP11B2 InhibitorCardiovascular · IND Filing · CYP11B2AssetsENPP1 InhibitorCardiovascular · IND Approved · ENPP1AssetsB7-H3 ADCOncology · Phase 1 · B7-H3AssetsATM InhibitorOncology · Phase 1 · ATMAssetsKAT6 InhibitorOncology · Phase 1 · KAT6A / KAT6BAssetsEGFR-ADCOncology · Phase 3 · EGFRAssetsNovaRock × Bionyra (2026)Exclusive license agreement for NBL-023, a novel anti–IL-25 monoclonal antibody, granting worldwide rights outside Greater China.TransactionsNovaRock × LigaChemBio (2026)Global out-licensing agreement for an ADC candidate targeting a novel oncology antigen.TransactionsCSPC × Radiance Biopharma (2025)$1,240 million strategic partnership for ROR1-ADC (SYS6005).TransactionsCSPC × Cipla (2025)$1,065 million strategic partnership for an Irinotecan Liposomal Injection product.TransactionsNovaRock × LigaChemBio (2025)Two global out-licensing agreements for novel antibodies.Transactions

THE EXPERIENCE BEHIND JEA

Your ambition. An experienced partner.

Independent strategic perspective, international relationships, and a personal commitment to moving your business forward.

John Adamou
John Adamou, MS, MBAPRESIDENT & MANAGING DIRECTOR

MEET JOHN

A career built
on connection.

John is a seasoned executive with 25+ years of experience in the biotech and pharma industries, specializing in strategy and business development. He has successfully executed 85 partnerships across multiple continents, resulting in over $25 billion in transaction value.

His expertise spans the entire BD value chain, including strategy, search and evaluation, deal structuring, transaction negotiation, and alliance management.

Through JEA BizDev Consulting, John advises biotech and biopharma companies on identifying, structuring, negotiating, and executing partnerships across North America, Europe, and Asia, with a particular focus on cross-border transactions.

25+

Years in healthcare leadership

85

Partnerships executed

$25B+

Total partnership value

Career experience across healthcare leadership and business development.

A BROAD PERSPECTIVE

Many structures.
One focus: value.

Cross-border expertise

Relationships and transaction experience across North America, Europe, and Asia.

Diverse deal structures

Platform technology agreements, collaborations, co-development alliances, asset acquisitions, and in- and out-licensing.

End-to-end perspective

Strategic counsel grounded in practical experience throughout the partnering process.

THE NEXT CONVERSATION COULD CHANGE EVERYTHING

Great science deserves
the right partnership.

Let’s talk about where you want to go,
and how we can help you get there.

Start a conversation